Poliomyelitis Epidemiology Forecast 2026-2035

Read more about this report - Request a Free Sample

Poliomyelitis Epidemiology Forecast Report Coverage

Expert Market Research's “Poliomyelitis Epidemiology Forecast Report 2026-2035” offers comprehensive information on the prevalence and demographics of poliomyelitis. It projects the future incidence and prevalence rates of poliomyelitis across various populations. The study covers age, gender, and type as major determinants of the poliomyelitis population. The report highlights patterns in the prevalence of poliomyelitis over time and projects future trends based on multiple variables.

Poliomyelitis Understanding: Disease Overview

The poliovirus is an infectious agent that causes poliomyelitis, or polio, which mainly affects children under five. It is spread by direct contact with an infected person, contaminated water, or fecal-oral transmission. When the virus enters the neural system, it can lead to respiratory failure, paralysis, and muscle weakness. Some infections cause death or lasting disability, although the majority are minor or asymptomatic. Though it is still a problem in some areas, worldwide immunization campaigns have greatly decreased the number of polio cases.

Poliomyelitis Epidemiology Perspective

The poliomyelitis epidemiology division offers information on the patient pool from history to the present as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for poliomyelitis by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for poliomyelitis and their trends. The data is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• According to the World Health Organization (WHO), out of the three wild poliovirus strains (type 1, type 2, and type 3), type 2 was eliminated in 1999, while type 3 was eliminated in 2020. Pakistan and Afghanistan are the two nations where endemic wild poliovirus type 1 was still present as of 2022.
• A study indicated that over time, the number of polio cases have drastically decreased. Over 50,000 cases of polio were reported globally in 1980. However, this figure dropped to 649 in 2021.
• Another study revealed that from an estimated 350, 000 cases in more than 125 endemic countries in 1988 to 140 cases reported in two countries in 2020. The global incidence of polio has dropped by more than 99% since the Global Polio Eradication Initiative (GPEI) was started in 1988 with the goal of eliminating all polio viruses.
• In worldwide campaigns, the oral polio vaccine was the most widely used vaccine, and endemic regions continue to use it. It has the benefit of promoting intestinal and humoral immunity. Because OPV is administered orally, bulk vaccination can be completed quickly and at a very low cost. The minor risk of vaccine-associated paralytic poliomyelitis (VAPP), which affects roughly 4 out of every 10,00,000 vaccinated children and unprotected contacts, is the drawback.
• According to the U.S. Centers for Disease Control and Prevention, inactivated polio vaccine (IPV) is 90% or more effective against paralytic polio after two doses, and 99% to 100% effective after three doses.

Read more about this report - Request a Free Sample

Country-wise Poliomyelitis Epidemiology Segment

The poliomyelitis epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of poliomyelitis varies between countries owing to the differences in factors such as genetic disorder, environmental factors and others. According to the World Health Organization (WHO), within ten years, if polio is not eradicated from its final remaining strongholds, there might be up to 200,000 new cases annually worldwide. Although, there were only 175 recorded instances of wild poliovirus in 2019, with majority of the cases in Afghanistan and Pakistan, there was a surprising number of outbreaks of circulating vaccine-derived poliovirus type 2 (cVDPV2), mostly in Africa but also in portions of the Middle East and South East Asia.

Key Questions Answered

• What are the key findings of poliomyelitis epidemiology in the 8 major markets?
• What will be the total number of patients with poliomyelitis across the 8 major markets during the forecast period?
• What was the country-wise prevalence of poliomyelitis in the 8 major markets in the historical period?
• Which country will have the highest number of poliomyelitis patients during the forecast period of 2026-2035?
• Which key factors would influence the shift in the patient population of poliomyelitis during the forecast period of 2026-2035?
• What are the currently available treatments for poliomyelitis market?
• What are the disease risks, signs, symptoms, and unmet needs of poliomyelitis?

Related Reports

Poliomyelitis Drug Pipeline Analysis Report